Aligos Therapeutics (NASDAQ:ALGS) Now Covered by Jefferies Financial Group

Investment analysts at Jefferies Financial Group assumed coverage on shares of Aligos Therapeutics (NASDAQ:ALGS) in a report issued on Monday, Zacks reports. The firm set a “strong-buy” rating on the stock.

A number of other research firms have also weighed in on ALGS. HC Wainwright restated a “buy” rating on shares of Aligos Therapeutics in a research note on Monday, August 10th. Weiss Ratings cut shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $38.50.

Aligos Therapeutics Price Performance

ALGS opened at $3.95 on Monday. Aligos Therapeutics has a 12 month low of $3.95 and a 12 month high of $13.69. The business has a fifty day moving average price of $5.25 and a 200 day moving average price of $6.15.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings results on Friday, November 6th. The company reported ($2.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.28) by $0.19. The company had revenue of $2.87 million for the quarter, compared to analyst estimates of $4.85 million. Aligos Therapeutics had a negative return on equity of 160.72% and a negative net margin of 241.01%. Research analysts anticipate that Aligos Therapeutics will post -6.81 EPS for the current year.

Institutional Trading of Aligos Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALGS. Renaissance Technologies LLC boosted its holdings in shares of Aligos Therapeutics by 17.6% in the 1st quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock valued at $746,000 after buying an additional 15,006 shares in the last quarter. SummitTX Capital L.P. grew its position in shares of Aligos Therapeutics by 6.7% in the 1st quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after buying an additional 9,375 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in Aligos Therapeutics by 1,652.8% during the 1st quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock worth $1,707,000 after acquiring an additional 216,646 shares in the last quarter. Institutional investors and hedge funds own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections.

Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH.